RenovoRx Ownership 2024 | Who Owns RenovoRx Now?

OverviewFinancials Chart

Institutional Ownership

1.69%

Insider Ownership

1.90%

Retail Ownership

96.41%

Institutional Holders

4.00

RenovoRx Institutional Shareholders

Institutional Shareholders by % of Total Shares

Name	% Total Shares	% Total Assets	Current Shares	Change Amount	Change %	Market Value	Date
ADAR1 CAPITAL MANAGEMENT, LLC	2.38%	0.08%	355,240	355,240	100.00%	401,421	Jun 30, 2024
GEODE CAPITAL MANAGEMENT, LLC	0.96%	-	143,919	76,831	114.52%	162,651	Jun 30, 2024
NIXON PEABODY TRUST CO	0.65%	0.01%	97,165	-	-	109,796	Jun 30, 2024
MILLENNIUM MANAGEMENT LLC	0.58%	-	86,316	86,316	100.00%	97,537	Jun 30, 2024
VANGUARD GROUP INC	0.38%	-	56,737	-	-	64,113	Jun 30, 2024
CHARLES SCHWAB INVESTMENT MANAGEMENT INC	0.33%	-	49,232	-	-	55,632	Jun 30, 2024
STATE STREET CORP	0.17%	-	26,152	7,300	38.72%	29,552,000	Jun 30, 2024
AFFINITY CAPITAL ADVISORS, LLC	0.09%	0.00%	13,279	-	-	15,005	Jun 30, 2024
HRT FINANCIAL LP	0.08%	0.00%	11,743	11,743	100.00%	13,000	Jun 30, 2024
RENAISSANCE TECHNOLOGIES LLC	0.07%	-	10,000	10,000	100.00%	11,300	Jun 30, 2024
BLACKROCK INC.	0.06%	-	9,162	-11,678	-56.04%	10,353	Jun 30, 2024
TOWER RESEARCH CAPITAL LLC (TRC)	0.05%	0.00%	7,389	1,120	17.87%	8,350	Jun 30, 2024
UBS GROUP AG	0.01%	-	1,305	1,305	100.00%	1,475	Jun 30, 2024
FAMILY FIRM, INC.	0.01%	0.00%	1,000	1,000	100.00%	1,130	Jun 30, 2024
BANK OF AMERICA CORP /DE/	0.00%	-	182	182	100.00%	206	Jun 30, 2024
WELLS FARGO & COMPANY/MN	-	-	-	-69	-100.00%	-	Jun 30, 2024

RenovoRx's largest institutional shareholder is ADAR1 CAPITAL MANAGEMENT, LLC, holding 2.38% of the company's total share outstanding, currently valued at $401.42K. The top 10 institutional shareholders own together 5.69% of the company.

Institutional Shareholders by % of Total Assets

Name	% Total Shares	% Total Assets	Current Shares	Change Amount	Change %	Market Value	Date
ADAR1 CAPITAL MANAGEMENT, LLC	2.38%	0.08%	355,240	355,240	100.00%	401,421	Jun 30, 2024
NIXON PEABODY TRUST CO	0.65%	0.01%	97,165	-	-	109,796	Jun 30, 2024
AFFINITY CAPITAL ADVISORS, LLC	0.09%	0.00%	13,279	-	-	15,005	Jun 30, 2024
FAMILY FIRM, INC.	0.01%	0.00%	1,000	1,000	100.00%	1,130	Jun 30, 2024
TOWER RESEARCH CAPITAL LLC (TRC)	0.05%	0.00%	7,389	1,120	17.87%	8,350	Jun 30, 2024
HRT FINANCIAL LP	0.08%	0.00%	11,743	11,743	100.00%	13,000	Jun 30, 2024
MILLENNIUM MANAGEMENT LLC	0.58%	-	86,316	86,316	100.00%	97,537	Jun 30, 2024
RENAISSANCE TECHNOLOGIES LLC	0.07%	-	10,000	10,000	100.00%	11,300	Jun 30, 2024
GEODE CAPITAL MANAGEMENT, LLC	0.96%	-	143,919	76,831	114.52%	162,651	Jun 30, 2024
CHARLES SCHWAB INVESTMENT MANAGEMENT INC	0.33%	-	49,232	-	-	55,632	Jun 30, 2024
STATE STREET CORP	0.17%	-	26,152	7,300	38.72%	29,552,000	Jun 30, 2024
VANGUARD GROUP INC	0.38%	-	56,737	-	-	64,113	Jun 30, 2024
UBS GROUP AG	0.01%	-	1,305	1,305	100.00%	1,475	Jun 30, 2024
BLACKROCK INC.	0.06%	-	9,162	-11,678	-56.04%	10,353	Jun 30, 2024
BANK OF AMERICA CORP /DE/	0.00%	-	182	182	100.00%	206	Jun 30, 2024
WELLS FARGO & COMPANY/MN	-	-	-	-69	-100.00%	-	Jun 30, 2024

The largest RenovoRx shareholder by % of total assets is ADAR1 CAPITAL MANAGEMENT, LLC. The company owns 355.24K shares of RenovoRx (RNXT), representing 0.08% of its total assets.

Institutional Buyers

Name	% Total Shares	% Total Assets	Current Shares	Change Amount	Change %	Market Value	Date
ADAR1 CAPITAL MANAGEMENT, LLC	2.38%	0.08%	355,240	355,240	100.00%	401,421	Jun 30, 2024
MILLENNIUM MANAGEMENT LLC	0.58%	-	86,316	86,316	100.00%	97,537	Jun 30, 2024
GEODE CAPITAL MANAGEMENT, LLC	0.96%	-	143,919	76,831	114.52%	162,651	Jun 30, 2024
HRT FINANCIAL LP	0.08%	0.00%	11,743	11,743	100.00%	13,000	Jun 30, 2024
RENAISSANCE TECHNOLOGIES LLC	0.07%	-	10,000	10,000	100.00%	11,300	Jun 30, 2024
STATE STREET CORP	0.17%	-	26,152	7,300	38.72%	29,552,000	Jun 30, 2024
UBS GROUP AG	0.01%	-	1,305	1,305	100.00%	1,475	Jun 30, 2024
TOWER RESEARCH CAPITAL LLC (TRC)	0.05%	0.00%	7,389	1,120	17.87%	8,350	Jun 30, 2024
FAMILY FIRM, INC.	0.01%	0.00%	1,000	1,000	100.00%	1,130	Jun 30, 2024
BANK OF AMERICA CORP /DE/	0.00%	-	182	182	100.00%	206	Jun 30, 2024
VANGUARD GROUP INC	0.38%	-	56,737	-	-	64,113	Jun 30, 2024
CHARLES SCHWAB INVESTMENT MANAGEMENT INC	0.33%	-	49,232	-	-	55,632	Jun 30, 2024
AFFINITY CAPITAL ADVISORS, LLC	0.09%	0.00%	13,279	-	-	15,005	Jun 30, 2024
NIXON PEABODY TRUST CO	0.65%	0.01%	97,165	-	-	109,796	Jun 30, 2024
WELLS FARGO & COMPANY/MN	-	-	-	-69	-100.00%	-	Jun 30, 2024
BLACKROCK INC.	0.06%	-	9,162	-11,678	-56.04%	10,353	Jun 30, 2024

As of Jun 30 2024, RenovoRx's largest institutional buyer is ADAR1 CAPITAL MANAGEMENT, LLC. The company purchased 355.24K stocks of RNXT, valued at $401.42K.

Institutional Sellers

Name	% Total Shares	% Total Assets	Current Shares	Change Amount	Change %	Market Value	Date
BLACKROCK INC.	0.06%	-	9,162	-11,678	-56.04%	10,353	Jun 30, 2024
WELLS FARGO & COMPANY/MN	-	-	-	-69	-100.00%	-	Jun 30, 2024
NIXON PEABODY TRUST CO	0.65%	0.01%	97,165	-	-	109,796	Jun 30, 2024
AFFINITY CAPITAL ADVISORS, LLC	0.09%	0.00%	13,279	-	-	15,005	Jun 30, 2024
CHARLES SCHWAB INVESTMENT MANAGEMENT INC	0.33%	-	49,232	-	-	55,632	Jun 30, 2024
VANGUARD GROUP INC	0.38%	-	56,737	-	-	64,113	Jun 30, 2024
BANK OF AMERICA CORP /DE/	0.00%	-	182	182	100.00%	206	Jun 30, 2024
FAMILY FIRM, INC.	0.01%	0.00%	1,000	1,000	100.00%	1,130	Jun 30, 2024
TOWER RESEARCH CAPITAL LLC (TRC)	0.05%	0.00%	7,389	1,120	17.87%	8,350	Jun 30, 2024
UBS GROUP AG	0.01%	-	1,305	1,305	100.00%	1,475	Jun 30, 2024
STATE STREET CORP	0.17%	-	26,152	7,300	38.72%	29,552,000	Jun 30, 2024
RENAISSANCE TECHNOLOGIES LLC	0.07%	-	10,000	10,000	100.00%	11,300	Jun 30, 2024
HRT FINANCIAL LP	0.08%	0.00%	11,743	11,743	100.00%	13,000	Jun 30, 2024
GEODE CAPITAL MANAGEMENT, LLC	0.96%	-	143,919	76,831	114.52%	162,651	Jun 30, 2024
MILLENNIUM MANAGEMENT LLC	0.58%	-	86,316	86,316	100.00%	97,537	Jun 30, 2024
ADAR1 CAPITAL MANAGEMENT, LLC	2.38%	0.08%	355,240	355,240	100.00%	401,421	Jun 30, 2024

As of Jun 30 2024, RenovoRx's biggest institutional seller is BLACKROCK INC.. The company sold -11.68K shares of RNXT, valued at $10.35K.

Institutional New positions

Name	% Total Shares	% Total Assets	Current Shares	Change Amount	Change %	Market Value	Date
ADAR1 CAPITAL MANAGEMENT, LLC	2.38%	0.08%	355,240	355,240	100.00%	401,421	Jun 30, 2024
MILLENNIUM MANAGEMENT LLC	0.58%	-	86,316	86,316	100.00%	97,537	Jun 30, 2024
RENAISSANCE TECHNOLOGIES LLC	0.07%	-	10,000	10,000	100.00%	11,300	Jun 30, 2024
UBS GROUP AG	0.01%	-	1,305	1,305	100.00%	1,475	Jun 30, 2024
FAMILY FIRM, INC.	0.01%	0.00%	1,000	1,000	100.00%	1,130	Jun 30, 2024

RenovoRx's largest new institutional shareholder by number of shares is ADAR1 CAPITAL MANAGEMENT, LLC, purchased 355.24K shares, valued at $401.42K, as of undefined.

Institutional Sold Out

Name	% Total Shares	% Total Assets	Current Shares	Change Amount	Change %	Market Value	Date
WELLS FARGO & COMPANY/MN	-	-	-	-69	-100.00%	-	Jun 30, 2024

RenovoRx's largest sold out institutional shareholder by shares sold is WELLS FARGO & COMPANY/MN, sold -69.00 shares, valued at -, as of undefined.

RenovoRx Mutual Fund Holders

Name	% Total Assets	Total Shares	Change Amount	Change %	Date
SCHWAB CAPITAL TRUST	0.00%	49,232	-	-	Jan 31, 2024
FIDELITY CONCORD STREET TRUST	0.00%	65,177	11,087	20.50%	Feb 29, 2024
VANGUARD INDEX FUNDS	0.00%	56,737	-56,419	-49.86%	Mar 31, 2024
USAA MUTUAL FUNDS TRUST	0.00%	910	-	-	Jan 31, 2024
iSHARES TRUST	0.00%	20,840	5,700	37.65%	Mar 31, 2024
EQ ADVISORS TRUST	0.00%	429	-	-	Mar 31, 2024

RenovoRx's largest mutual fund holder by % of total assets is "SCHWAB CAPITAL TRUST", owning 49.23K shares, compromising 0.00% of its total assets.

RenovoRx Institutional Ownership Trends

Institutional Holdings Trend

Date	Holdings	Change %
30 Jun, 24	4	-55.56%
31 Mar, 24	9	-18.18%
31 Dec, 23	11	-21.43%
30 Sep, 23	14	55.56%
30 Jun, 23	9	-25.00%
31 Mar, 23	12	9.09%
31 Dec, 22	11	-8.33%
30 Sep, 22	12	33.33%
30 Jun, 22	9	-10.00%
31 Mar, 22	10	42.86%
31 Dec, 21	7	-12.50%
30 Sep, 21	8	-

As of 30 Jun 24, 4 institutions are holding RenovoRx's shares, representing a decrease of -55.56% compared to the previous quarter.

Shares Outstanding Trend

Date	Shares Outstanding	Change %
30 Jun, 24	252,084	-23.50%
31 Mar, 24	329,531	-0.47%
31 Dec, 23	331,078	-8.95%
30 Sep, 23	363,630	48.82%
30 Jun, 23	244,336	-88.83%
31 Mar, 23	2,186,907	87.06%
31 Dec, 22	1,169,112	-1.52%
30 Sep, 22	1,187,111	-0.08%
30 Jun, 22	1,188,008	621.19%
31 Mar, 22	164,728	57.85%
31 Dec, 21	104,357	-38.30%
30 Sep, 21	169,148	-

RenovoRx (RNXT) has 252.08K shares outstanding as of 30 Jun 24, down -23.50% compared to the previous quarter.

Institutional Ownership Trend

Date	Ownership %	Change %
30 Jun, 24	1.69%	17.76%
31 Mar, 24	3.08%	32.15%
31 Dec, 23	3.10%	26.59%
30 Sep, 23	3.41%	47.23%
30 Jun, 23	2.69%	0.46%
31 Mar, 23	24.06%	14.42%
31 Dec, 22	12.92%	7.54%
30 Sep, 22	13.09%	7.61%
30 Jun, 22	13.12%	390.87%
31 Mar, 22	1.83%	53.13%
31 Dec, 21	1.86%	20.50%
30 Sep, 21	3.01%	-

As of 30 Jun 24, RenovoRx is held by 1.69% institutional shareholders, representing a 17.76% growth compared to 31 Mar 24.

Institutional Increased Positions Trend

Date	Increased Positions	Change %
30 Jun, 24	3	-25.00%
31 Mar, 24	4	-33.33%
31 Dec, 23	6	-25.00%
30 Sep, 23	8	60.00%
30 Jun, 23	5	-37.50%
31 Mar, 23	8	60.00%
31 Dec, 22	5	25.00%
30 Sep, 22	4	-20.00%
30 Jun, 22	5	-44.44%
31 Mar, 22	9	125.00%
31 Dec, 21	4	-50.00%
30 Sep, 21	8	-

3 institutional shareholders have increased their position in RNXT stock as of 30 Jun 24 compared to 4 in the previous quarter (a -25.00% decrease).

Institutional Reduced Positions Trend

Date	Reduced Positions	Change %
30 Jun, 24	-	-100.00%
31 Mar, 24	1	-
31 Dec, 23	1	-50.00%
30 Sep, 23	2	-
30 Jun, 23	-	-100.00%
31 Mar, 23	3	-
31 Dec, 22	3	-25.00%
30 Sep, 22	4	100.00%
30 Jun, 22	2	-
31 Mar, 22	-	-100.00%
31 Dec, 21	2	-
30 Sep, 21	-	-

- institutional shareholders have reduced their position in RNXT stock as of 30 Jun 24 compared to 1 in the previous quarter (a -100.00% decrease).

All Institutional Ownership Trend Data

Date	Holdings	Change %	Shares Outstanding	Change %	Ownership %	Change %	Increased Positions	Change %	Reduced Positions	Change %
30 Jun, 24	4	-55.56%	252,084	-23.50%	1.69%	17.76%	3	-25.00%	-	-100.00%
31 Mar, 24	9	-18.18%	329,531	-0.47%	3.08%	32.15%	4	-33.33%	1	-
31 Dec, 23	11	-21.43%	331,078	-8.95%	3.10%	26.59%	6	-25.00%	1	-50.00%
30 Sep, 23	14	55.56%	363,630	48.82%	3.41%	47.23%	8	60.00%	2	-
30 Jun, 23	9	-25.00%	244,336	-88.83%	2.69%	0.46%	5	-37.50%	-	-100.00%
31 Mar, 23	12	9.09%	2,186,907	87.06%	24.06%	14.42%	8	60.00%	3	-
31 Dec, 22	11	-8.33%	1,169,112	-1.52%	12.92%	7.54%	5	25.00%	3	-25.00%
30 Sep, 22	12	33.33%	1,187,111	-0.08%	13.09%	7.61%	4	-20.00%	4	100.00%
30 Jun, 22	9	-10.00%	1,188,008	621.19%	13.12%	390.87%	5	-44.44%	2	-
31 Mar, 22	10	42.86%	164,728	57.85%	1.83%	53.13%	9	125.00%	-	-100.00%
31 Dec, 21	7	-12.50%	104,357	-38.30%	1.86%	20.50%	4	-50.00%	2	-
30 Sep, 21	8	-	169,148	-	3.01%	-	8	-	-	-

RenovoRx Insider Shareholders Trades

Open Market Insider Trades

Date	Name	Relation	Role	Transaction	Buy/Sell	Shares	Price	Value	Shares Held
Jan 30, 2024	Agah Ramtin	director, officer	Chief Medical Officer	P-Purchase	Buy	40,983	$1.22	$50.00K	47,460
Jan 30, 2024	Agah Ramtin	director, officer	Chief Medical Officer	P-Purchase	Buy	40,983	$1.22	$50.00K	40,983
Jan 30, 2024	Spiegel Robert J.	director	-	P-Purchase	Buy	40,983	$1.22	$50.00K	40,983
Jan 30, 2024	Spiegel Robert J.	director	-	P-Purchase	Buy	40,983	$1.22	$50.00K	40,983
Jan 30, 2024	Bagai Shaun	director, officer	Chief Executive Officer	P-Purchase	Buy	40,983	$1.22	$50.00K	292,540
Jan 30, 2024	Bagai Shaun	director, officer	Chief Executive Officer	P-Purchase	Buy	40,983	$1.22	$50.00K	40,983
Jan 30, 2024	Marton Laurence	director	-	P-Purchase	Buy	8,196	$1.22	$10.00K	33,634
Jan 30, 2024	Marton Laurence	director	-	P-Purchase	Buy	8,196	$1.22	$10.00K	8,196
Jan 30, 2024	Macfarlane K. Angela	director	-	P-Purchase	Buy	40,983	$1.22	$50.00K	40,983
Jan 30, 2024	Macfarlane K. Angela	director	-	P-Purchase	Buy	40,983	$1.22	$50.00K	40,983

Open Market Insider Buys

Date	Name	Relation	Role	Transaction	Buy/Sell	Shares	Price	Value	Shares Held
Jan 30, 2024	Agah Ramtin	director, officer	Chief Medical Officer	P-Purchase	Buy	40,983	$1.22	$50.00K	47,460
Jan 30, 2024	Agah Ramtin	director, officer	Chief Medical Officer	P-Purchase	Buy	40,983	$1.22	$50.00K	40,983
Jan 30, 2024	Spiegel Robert J.	director	-	P-Purchase	Buy	40,983	$1.22	$50.00K	40,983
Jan 30, 2024	Spiegel Robert J.	director	-	P-Purchase	Buy	40,983	$1.22	$50.00K	40,983
Jan 30, 2024	Bagai Shaun	director, officer	Chief Executive Officer	P-Purchase	Buy	40,983	$1.22	$50.00K	292,540
Jan 30, 2024	Bagai Shaun	director, officer	Chief Executive Officer	P-Purchase	Buy	40,983	$1.22	$50.00K	40,983
Jan 30, 2024	Marton Laurence	director	-	P-Purchase	Buy	8,196	$1.22	$10.00K	33,634
Jan 30, 2024	Marton Laurence	director	-	P-Purchase	Buy	8,196	$1.22	$10.00K	8,196
Jan 30, 2024	Macfarlane K. Angela	director	-	P-Purchase	Buy	40,983	$1.22	$50.00K	40,983
Jan 30, 2024	Macfarlane K. Angela	director	-	P-Purchase	Buy	40,983	$1.22	$50.00K	40,983

Insider Sells

Date	Name	Relation	Role	Buy/Sell	Shares	Price	Value	Shares Held
Mar 08, 2024	Gentry Leesa	officer	Chief Clinical Officer	Sell	62,500	$2.11	$131.88K	-
Mar 08, 2024	Gentry Leesa	officer	Chief Clinical Officer	Sell	60,159	$1.08	$64.97K	-
Feb 12, 2024	Kocak Ron	officer	VP, Controller and PAO	Sell	34,390	$2.19	$75.31K	-
Feb 12, 2024	Kocak Ron	officer	VP, Controller and PAO	Sell	15,875	$3.29	$52.23K	-
Feb 12, 2024	Kocak Ron	officer	VP, Controller and PAO	Sell	3,000	$2.11	$6.33K	-
Feb 12, 2024	Kocak Ron	officer	VP, Controller and PAO	Sell	12,248	$1.08	$13.23K	-
Feb 12, 2024	Kocak Ron	officer	VP, Controller and PAO	Sell	48,128	$1.08	$51.98K	-

All Insider Owners Trades

Date	Name	Relation	Role	Transaction	Buy/Sell	Shares	Price	Value	Shares Held
Mar 08, 2024	Gentry Leesa	officer	Chief Clinical Officer	A-Award	Buy	190,000	$1.69	$321.10K	190,000
Mar 08, 2024	Gentry Leesa	officer	Chief Clinical Officer		Sell	62,500	$2.11	$131.88K	-
Mar 08, 2024	Gentry Leesa	officer	Chief Clinical Officer		Sell	60,159	$1.08	$64.97K	-
Feb 12, 2024	Kocak Ron	officer	VP, Controller and PAO	A-Award	Buy	15,000	$1.59	$23.85K	15,000
Feb 12, 2024	Kocak Ron	officer	VP, Controller and PAO		Sell	34,390	$2.19	$75.31K	-
Feb 12, 2024	Kocak Ron	officer	VP, Controller and PAO		Sell	15,875	$3.29	$52.23K	-
Feb 12, 2024	Kocak Ron	officer	VP, Controller and PAO		Sell	3,000	$2.11	$6.33K	-
Feb 12, 2024	Kocak Ron	officer	VP, Controller and PAO		Sell	12,248	$1.08	$13.23K	-
Feb 12, 2024	Kocak Ron	officer	VP, Controller and PAO		Sell	48,128	$1.08	$51.98K	-
Jan 30, 2024	Agah Ramtin	director, officer	Chief Medical Officer	P-Purchase	Buy	40,983	$1.22	$50.00K	47,460
Jan 30, 2024	Agah Ramtin	director, officer	Chief Medical Officer	P-Purchase	Buy	40,983	$1.22	$50.00K	40,983
Jan 30, 2024	Spiegel Robert J.	director	-	P-Purchase	Buy	40,983	$1.22	$50.00K	40,983
Jan 30, 2024	Spiegel Robert J.	director	-	P-Purchase	Buy	40,983	$1.22	$50.00K	40,983
Jan 30, 2024	Bagai Shaun	director, officer	Chief Executive Officer	P-Purchase	Buy	40,983	$1.22	$50.00K	292,540
Jan 30, 2024	Bagai Shaun	director, officer	Chief Executive Officer	P-Purchase	Buy	40,983	$1.22	$50.00K	40,983
Jan 30, 2024	Marton Laurence	director	-	P-Purchase	Buy	8,196	$1.22	$10.00K	33,634
Jan 30, 2024	Marton Laurence	director	-	P-Purchase	Buy	8,196	$1.22	$10.00K	8,196
Jan 30, 2024	Macfarlane K. Angela	director	-	P-Purchase	Buy	40,983	$1.22	$50.00K	40,983
Jan 30, 2024	Macfarlane K. Angela	director	-	P-Purchase	Buy	40,983	$1.22	$50.00K	40,983
Jan 23, 2024	Nelms Angela	officer	Chief Operating Officer	A-Award	Buy	125,132	$1.08	$135.14K	125,132

The last insider sell of RenovoRx's stock was made by Gentry Leesa on Mar 08 2024, selling 62,500 shares at $2.11 per share (valued at $131.88K). The last insider buy of RNXT was made by Agah Ramtin on Jan 30 2024, buying 40,983 shares at $1.22 per share (worth $50.00K).

RenovoRx Insider Ownership Trends

All Insider Trades Trend

Date	Buy	Sell	Buy/Sell Ratio
Q1 2024	18	3	600.00%
Q4 2023	7	-	-
Q2 2023	1	2	50.00%
Q1 2023	3	1	300.00%
Q4 2022	5	1	500.00%
Q3 2022	1	1	100.00%
Q2 2022	2	1	200.00%
Q1 2022	5	2	250.00%
Q4 2021	5	-	-
Q3 2021	4	19	21.05%

18 total buy trades, and 3 total sell trades (buy/sell ratio of 6.00%) were made by RenovoRx's insiders, as of Q1 2024.

Open Market Insider Trades Trend

Date	Buy	Sell	Buy/Sell Ratio
Q1 2024	10	-	-
Q4 2023	2	-	-
Q2 2023	-	-	-
Q1 2023	-	-	-
Q4 2022	-	-	-
Q3 2022	-	-	-
Q2 2022	2	-	-
Q1 2022	-	-	-
Q4 2021	-	-	-
Q3 2021	-	-	-

As of Q1 2024, Insider owners conducted 10 open market buy trades and 0 open market sell trades of RenovoRx's stocks.

RenovoRx Peer Ownership

Ticker	Company
NTRB	Nutriband Inc.
AXLA	Axcella Health Inc.
MNPR	Monopar Therapeutics Inc.
ADIL	Adial Pharmaceuticals, Inc.
IKNA	Ikena Oncology, Inc.
SABS	SAB Biotherapeutics, Inc.
KTTA	Pasithea Therapeutics Corp.
LGVN	Longeveron Inc.
QNRX	Quoin Pharmaceuticals, Ltd.
VRAX	Virax Biolabs Group Limited
ELDN	Eledon Pharmaceuticals, Inc.
TPST	Tempest Therapeutics, Inc.
ANEB	Anebulo Pharmaceuticals, Inc.
ABIO	ARCA biopharma, Inc.
CBIO	Gyre Therapeutics, Inc.

RNXT Ownership FAQ

Who Owns RenovoRx?

RenovoRx is owned by institutional shareholders (1.69%), insiders (1.90%), and public (96.41%). The largest institutional shareholder of RenovoRx is ADAR1 CAPITAL MANAGEMENT, LLC (2.38% of total shares) and the top mutual fund owner is SCHWAB CAPITAL TRUST (0.00% of total shares).

Who are the major institutional shareholders of RenovoRx?

RenovoRx's major institutional shareholders are ADAR1 CAPITAL MANAGEMENT, LLC, GEODE CAPITAL MANAGEMENT, LLC, NIXON PEABODY TRUST CO, MILLENNIUM MANAGEMENT LLC, and VANGUARD GROUP INC. The top five shareholders own together 4.95% of the company's share outstanding.

How many RenovoRx shareholders are there?

As of Jun 2024, there are 4 institutional shareholders of RenovoRx.

What percentage of RenovoRx is owned by ADAR1 CAPITAL MANAGEMENT, LLC?

ADAR1 CAPITAL MANAGEMENT, LLC owns 355.24K shares of RenovoRx, representing 2.38% of the company's total shares outstanding, valued at $401.42K (as of Jun 2024).

What percentage of RenovoRx is owned by GEODE CAPITAL MANAGEMENT, LLC?

As of Jun 2024, GEODE CAPITAL MANAGEMENT, LLC holds 143.92K shares of RenovoRx (RNXT), compromising 0.96% of the company, valued at $162.65K.

What percentage of RenovoRx is owned by NIXON PEABODY TRUST CO?

NIXON PEABODY TRUST CO is the third largest holder of RenovoRx. The company owns 97.16K of the company's shares outstanding (worth $109.8K).